Science Member
Institution: Yale University | Sign In as Individual | FAQ | Access Rights | Join AAAS
HelpSubscriptionsFeedbackSign In

PDF Version of this Article
dEbates: Submit a response to this article
 
Related commentary and articles in Science products
 
Download to Citation Manager
Alert me when:
new articles cite this article
 
Search for similar articles in:
  Science Online
  PubMed
Search Medline for articles by:
Gerstein, M. || Montelione, G. T.

Structural Genomics: Current Progress

In his News Focus "Tapping DNA for structures produces a trickle" (1 Nov., p. 948), Robert Service presents an informative viewpoint about the progress of the structural genomics consortia. He describes how a number of consortia have targeted a vast number of proteins but only solved a small fraction of them. Although this is true, it is important to realize that structural genomics projects have been organized to evaluate large numbers of candidate targets, often of the same protein in different organisms, and simultaneously work on them in parallel. The aim is to determine the structure of representatives of particular protein families; thus, the representatives that do not come to fruition are not necessarily failures but are often simply the consequence of success elsewhere. For example, according to the International Structural Genomics Target Tracking Database (1), over 360 new three-dimensional protein structures have been completed by the various consortia and many more are nearly done. These proteins, which were selected because of their unique position in sequence space, have actually shed light on further thousands of homologous proteins whose structures can now be modeled for the first time. Thus, the output of structural genomics is highly leveraged, being much greater than the absolute number of new experimental structures.

Moreover, the number of targets selected does not represent a final end-point for the current structural genomics consortia in the way that the entire human genome represented an end-point for genome sequencing. The current consortia, in fact, represent pilot projects with a primary mandate of testing multiple technologies in order to identify the best procedures for scaling up. Accordingly, the "success rates" reported by Service represent snapshots of an ongoing iterative process. For many of the protein targets reported as being "selected," no effort has even been made yet to clone or express them. Consequently, comparing outcome versus number of "selected" targets can result in a somewhat misleading picture of the current progress of the nascent structural genomics efforts.

M. Gerstein,*
Department of Molecular Biophysics and Biochemistry,
Yale University,
New Haven, CT 06520,
USA.

A. Edwards,*
Banting and Best Department of Medical Research,
C. H. Best Institute,
University of Toronto,
Toronto M5G 2M9,
Canada.

C. H. Arrowsmith,*
Department of Medical Biophysics,
Ontario Cancer Institute,
University of Toronto,
Toronto M5G 2M9,
Canada.

G. T. Montelione*
Department of Molecular Biology and Biochemistry,
Center for Advanced Biotechnology and Medicine,
Rutgers University and Robert Wood Johnson Medical School,
UMDNJ,
Piscataway, NJ 08854,
USA.

*Members of the Northeast Structural Genomics Consortium (nesg.org) of the NIH-sponsored Protein Structure Initiative

Reference

  1. See http://targetdb.rutgers.edu.
PDF Version of this Article
dEbates: Submit a response to this article
 
Related commentary and articles in Science products
 
Download to Citation Manager
Alert me when:
new articles cite this article
 
Search for similar articles in:
  Science Online
  PubMed
Search Medline for articles by:
Gerstein, M. || Montelione, G. T.

Related articles in Science:

STRUCTURAL GENOMICS:
Tapping DNA for Structures Produces a Trickle

Robert F. Service
Science 2002 298: 948-950. (in News Focus) [Summary] [Full Text]  


Volume 299, Number 5613, Issue of 14 Mar 2003, p. 1663.
Copyright © 2003 by The American Association for the Advancement of Science. All rights reserved.

GrantsNet